Johnson & Johnson is “confident” its blockbuster, next-generation Darzalex Faspro for multiple myeloma is a separate product from its predecessor, which would excuse it from Medicare price negotiation at the same time, according to J&J Innovative Medicine worldwide chair Jennifer Taubert.
Darzalex, Medicare Negotiation And The Strategic Importance Of Combination Products
Second generation combination products may become more appealing as companies navigate the complexities of the Medicare price negotiation program.
